# FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction

> **NCT05703997** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 20 (estimated)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DIETARY_SUPPLEMENT:** Cyclic, 5-day calorie restriction
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT05703997
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-01
- **Primary completion:** 2025-01
- **Final completion:** 2029-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-01-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05703997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05703997, "FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05703997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*